Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/12/2025

SSRI Side Effects and Contraindications

Common Side Effects

  • The American Academy of Child and Adolescent Psychiatry reports that SSRIs are generally well-tolerated but produce a broad range of side effects that are more common and persistent in real-world practice than clinical trials suggest, with most emerging within the first few weeks of treatment 1
  • Nausea, diarrhea, dry mouth, and heartburn are among the most frequently reported gastrointestinal symptoms 1
  • Sweating, tremors, and dizziness commonly occur across all SSRIs 2, 3
  • Insomnia or somnolence (drowsiness) affects approximately 17% of patients and is rated as particularly bothersome 1
  • Headache, nervousness, vivid dreams, and fatigue are frequently reported 1
  • Behavioral activation/agitation (motor restlessness, impulsiveness, disinhibited behavior, aggression) occurs more commonly in younger children than adolescents and typically emerges early in treatment or with dose increases 1
  • Sexual side effects (erectile dysfunction, delayed ejaculation, anorgasmia) occur in approximately 17% of patients and are among the most bothersome adverse effects 1
  • Weight changes (gain or loss) and appetite changes are common 1
  • Bruxism (teeth grinding) and tremor occur with regular frequency 1

Serious Adverse Effects Requiring Monitoring

  • All SSRIs carry a black box warning for suicidal thinking and behavior through age 24 years 1
  • Pooled absolute risk is 1% for antidepressant-treated youth vs. 0.2% for placebo (risk difference 0.7%, NNH = 143) 1
  • Close monitoring is mandatory, especially during the first months of treatment and following dose adjustments 1
  • Life-threatening condition caused by elevated brain serotonin levels, typically when SSRIs are combined with other serotonergic medications 1
  • Symptoms of serotonin syndrome arise within 24-48 hours and include mental status changes (confusion, agitation), neuromuscular hyperactivity (tremors, clonus, hyperreflexia, muscle rigidity), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis) 1
  • Advanced symptoms of serotonin syndrome include fever, seizures, arrhythmias, and unconsciousness leading to potential fatalities 1
  • Treatment of serotonin syndrome requires immediate hospitalization, discontinuation of all serotonergic agents, and supportive care with continuous cardiac monitoring 1
  • Mania/Hypomania is a rare but serious side effect, typically appearing later in treatment (beyond first month) rather than early like behavioral activation 1
  • Mania may persist after SSRI discontinuation and require active pharmacological intervention 1
  • Abnormal bleeding can occur, especially with concomitant aspirin or NSAID use 1
  • Rare bleeding events include ecchymosis, hematoma, epistaxis, petechiae, and hemorrhage 1
  • Seizures have been observed with SSRI use; use cautiously in patients with seizure disorder history 1

Contraindications

  • Concomitant use with monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome 1
  • Seizure disorders: Use with extreme caution given observed seizure risk 1
  • Concomitant use of other serotonergic medications: Significantly increases serotonin syndrome risk 1
  • Bleeding disorders or concurrent anticoagulant/antiplatelet therapy: Requires careful monitoring 1
  • Bipolar disorder: Risk of precipitating mania/hypomania 1

Drug Interactions

  • SSRIs may prolong half-life of other drugs by inhibiting various cytochrome P450 isoenzymes 2, 3
  • Fluvoxamine requires particular caution with alprazolam or triazolam 2, 3
  • Sertraline has less effect on metabolism of other medications compared to other SSRIs 2, 3

Special Populations

  • Behavioral activation/agitation is more common in younger children than adolescents 1
  • Slow up-titration minimizes behavioral activation and helps avoid exceeding optimal dose 1
  • Maximal therapeutic improvement typically occurs by week 12 or later, supporting gradual dose adjustments 1